EHA 2019 | MRD detection with NGS for AML: a new era of diagnostics
Torsten Haferlach
• 19 Jun 2019
Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, sheds light on a potential of a new era in diagnostics with the use of next-generation sequencing (NGS) for detecting measurable residual disease (MRD) status. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
